Stocktoria
Phathom Pharmaceuticals, Inc. PHAT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-10-25
Phathom Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $175.1M | $55.3M | $682,000 | $0 | — |
| Gross profit | $152.5M | $47.3M | $515,000 | $0 | — |
| R&D expense | $32.8M | $34.1M | $49.9M | $71.4M | $72.3M |
| SG&A expense | $279.7M | $290.7M | $117.9M | $101.0M | — |
| Operating income | -$160.0M | -$277.5M | -$167.3M | -$172.4M | -$135.1M |
| Interest expense | — | — | $42.0M | $27.3M | $6.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$221.2M | -$334.3M | -$201.6M | -$197.7M | -$143.9M |
| EPS (diluted) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 |
| Operating cash flow | -$166.8M | -$266.8M | -$137.6M | -$146.5M | -$148.5M |
| Free cash flow | -$167.0M | -$266.9M | -$139.2M | -$147.6M | -$148.8M |
| Cash & equivalents | $130.0M | $297.3M | $381.4M | $155.4M | $183.3M |
| Inventory | $5.5M | $3.2M | $1.2M | $0 | — |
| Total assets | $259.1M | $378.3M | $413.8M | $164.8M | $189.4M |
| Total liabilities | $697.3M | $631.9M | $486.6M | $239.6M | $117.3M |
| Shareholders' equity | -$438.2M | -$253.6M | -$72.8M | -$74.8M | $72.2M |
Source: SEC EDGAR filings · CIK 0001783183 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.